Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients

被引:32
作者
Cariani, Elisabetta [3 ]
Pollara, Caterina P. [1 ,2 ]
Valloncini, Barbara [1 ,2 ]
Perandin, Francesca [1 ,2 ]
Bonfanti, Carlo [1 ,2 ]
Manca, Nino [1 ,2 ]
机构
[1] Univ Brescia, Dept Expt & Appl Med, Microbiol Sect, Brescia, Italy
[2] AO Spedali Civili, Brescia, Italy
[3] Osped Civile S Agostino Estense, Lab Patol Clin, I-414041 Baggiovara, MO, Italy
关键词
D O I
10.1186/1471-2334-7-138
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Quantitative real-time PCR assays, which are more rapid and practical than pp65 antigenemia determination, are progressively becoming the preferred method for monitoring Human Cytomegalovirus (HCMV) reactivation. However, the relationship between HCMV DNA and antigenemia levels is still under investigation. The aim of this study was to analyse the relationship between HCMV DNA and pp65 antigenemia levels in order to identify clinically useful threshold values for the management of patients. Methods: 475 consecutive samples from 156 immunosuppressed patients were tested for HCMV by pp65 antigenemia and Real-time PCR assay. Results: 136 out of 475 consecutive samples derived from 48 patients showed evidence of HCMV infection. HCMV DNA was detected in 106 samples, pp65 antigen in 3, and both markers in 27. pp65 antigen detection was associated with higher HCMV DNA levels. The cut-off HCMV DNA level that best predicted pp65 antigenemia in this series of samples was 11,500 copies/ml, but different threshold levels could be observed for specific groups of patients. HCMV disease was observed in 5 out of 48 patients with active HCMV infection. The presence of clinical symptoms was associated with positive pp65 and with higher antigenemia levels. Higher HCMV DNA load at the onset of viral replication was correlated to the development of clinical symptoms. Conclusion: Both pp65 antigenemia and HCMV DNA load can be useful for the prospective monitoring of immunocompromised subjects. Specific cut-off levels capable of triggering preemptive antiviral treatment should be determined in accordance to the type of test used and the characteristics of patients and prospectively validated.
引用
收藏
页数:7
相关论文
共 28 条
[1]   CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays [J].
Amorim, ML ;
Cabeda, JM ;
Seca, R ;
Mendes, AC ;
Castro, AP ;
Amorim, JM .
BMC INFECTIOUS DISEASES, 2001, 1 (1)
[2]   FACTORS INFLUENCING DETECTION OF QUANTITATIVE CYTOMEGALOVIRUS ANTIGENEMIA [J].
BOECKH, M ;
WOOGERD, PM ;
STEVENSAYERS, T ;
RAY, CG ;
BOWDEN, RA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (03) :832-834
[3]   A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation [J].
Gentile, Giuseppe ;
Picardi, Alessandra ;
Capobianchi, Angela ;
Spagnoli, Alessandra ;
Cudillo, Laura ;
Dentamaro, Teresa ;
Tendas, Andrea ;
Cupelli, Luca ;
Ciotti, Marco ;
Volpi, Antonio ;
Amadori, Sergio ;
Martino, Pietro ;
de Fabritiis, Paolo .
BMC INFECTIOUS DISEASES, 2006, 6 (1)
[4]   Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events [J].
Gerna, G ;
Percivalle, E ;
Baldanti, F ;
Sozzani, S ;
Lanzarini, P ;
Genini, E ;
Lilleri, D ;
Revello, MG .
JOURNAL OF VIROLOGY, 2000, 74 (12) :5629-5638
[5]   Evaluation of CMV viral load using Taqman™ CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients [J].
Guiver, M ;
Fox, AJ ;
Mutton, K ;
Mogulkoc, N ;
Egan, J .
TRANSPLANTATION, 2001, 71 (11) :1609-1615
[6]   Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection [J].
Kalpoe, JS ;
Kroes, ACM ;
de Jong, MD ;
Schinkel, J ;
de Brouwer, CS ;
Beersma, MFC ;
Claas, ECJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) :1498-1504
[7]   Development and evaluation of a real-time quantitative PCR for the detection of human cytomegalovirus [J].
Kearns, AM ;
Guiver, M ;
James, V ;
King, J .
JOURNAL OF VIROLOGICAL METHODS, 2001, 95 (1-2) :121-131
[8]   Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation [J].
Kim, CK ;
Song, JH ;
Kim, SM ;
Peck, KR ;
Oh, W ;
Huh, W ;
Kim, YG ;
Kim, SJ ;
Joh, JW ;
Lee, NY ;
Park, CG ;
Hwang, ES ;
Cha, CY ;
Oh, HY .
TRANSPLANTATION, 2003, 75 (12) :2151-2155
[9]   Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients [J].
Kusne, S ;
Grossi, P ;
Irish, W ;
St George, K ;
Rinaldo, C ;
Rakela, J ;
Fung, J .
TRANSPLANTATION, 1999, 68 (08) :1125-1131
[10]   Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma [J].
Leruez-Ville, M ;
Ouachée, M ;
Delarue, R ;
Sauget, AS ;
Blanche, S ;
Buzyn, A ;
Rouzioux, C .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (05) :2040-2046